PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice

医学 临床实习 脑转移 肿瘤科 内科学 癌症 转移 家庭医学
作者
Iñaki Eguren‐Santamaría,Miguel F. Sanmamed,Sarah B. Goldberg,Harriet M. Kluger,Miguel Á. Idoate,Benjamin Y. Lu,J. Corral,Kurt A. Schalper,Roy S. Herbst,Ignacio Gil‐Bazo
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:26 (16): 4186-4197 被引量:81
标识
DOI:10.1158/1078-0432.ccr-20-0798
摘要

Abstract Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced non–small cell lung cancer (NSCLC). However, most pivotal phase III trials systematically excluded patients with active brain metastases, precluding the generalization of the results. Although theoretically restricted from crossing the blood–brain barrier, the novel pharmacokinetic/pharmacodynamic profiles of anti-PD-1/PD-L1 drugs have prompted studies to evaluate their activity in patients with NSCLC with active central nervous system (CNS) involvement. Encouraging results have suggested that ICI could be active in the CNS in selected patients with driver-negative advanced NSCLC with high PD-L1 expression and low CNS disease burden. Single-agent CNS response rates around 30% have been reported. Beyond this particular setting, anti-PD-1/PD-L1 antibodies have been evaluated in patients receiving local therapy for brain metastases (BM), addressing concerns about potential neurologic toxicity risks associated with radiotherapy, more specifically, radionecrosis (RN). Accordingly, a variety of clinical and imaging strategies are being appropriately developed to evaluate tumor response and to rule out pseudoprogression or radionecrosis. Our purpose is to critically summarize the advances regarding the role of systemic anti-PD-1/PD-L1 antibodies for the treatment of NSCLC BM. Data were collected from the PubMed database, reference lists, and abstracts from the latest scientific meetings. Recent reports suggest anti-PD-1/PD-L1 agents are active in a subset of patients with NSCLC with BM showing acceptable toxicity. These advances are expected to change soon the management of these patients but additional research is required to address concerns regarding radionecrosis and the appropriate sequencing of local and systemic therapy combinations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
2秒前
3秒前
翊悠yo完成签到 ,获得积分10
3秒前
大个的应助被勤恳依秋采纳,获得10
4秒前
4秒前
jxjsyf发布了新的文献求助30
5秒前
快乐小狗完成签到,获得积分10
5秒前
5秒前
5秒前
坦率雁卉发布了新的文献求助10
5秒前
ding的应助被快乐的问儿采纳,获得10
6秒前
史文韬发布了新的文献求助10
7秒前
9秒前
zhongqiu发布了新的文献求助30
10秒前
小卜同学完成签到,获得积分10
10秒前
11秒前
坦率雁卉完成签到,获得积分10
12秒前
经十路以东的应助被yiris采纳,获得10
12秒前
师专第一黑奴完成签到,获得积分10
14秒前
星星发布了新的文献求助10
14秒前
15秒前
15秒前
15秒前
Sushi完成签到,获得积分10
15秒前
16秒前
16秒前
16秒前
任雨净发布了新的文献求助10
16秒前
谋勇兼备发布了新的文献求助100
17秒前
WHZ完成签到,获得积分20
17秒前
谋勇兼备发布了新的文献求助100
17秒前
JenifferF发布了新的文献求助30
17秒前
多摩川的烟花少年完成签到,获得积分10
18秒前
xuwenli完成签到,获得积分20
18秒前
Zhang发布了新的文献求助10
18秒前
Sushi发布了新的文献求助10
19秒前
xc发布了新的文献求助10
19秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194415
求助须知:如何正确求助?哪些是违规求助? 9580155
关于积分的说明 21870088
捐赠科研通 7793967
什么是DOI,文献DOI怎么找? 3437647
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484376